NeuroSense initiated with a Buy at D. Boral Capital

D. Boral Capital analyst Jason Kolbert initiated coverage of NeuroSense (NRSN) with a Buy rating and $14 price target NeuroSense is a clinical-stage biotechnology company advancing a novel combination therapy platform targeting neurodegenerative diseases, with its lead candidate, PrimeC, in development for amyotrophic lateral sclerosis, the analyst tells investors in a research note. The firm says its bullish stance is supported by a “differentiated mechanistic approach, encouraging early clinical signals, and a disciplined strategy toward regulatory and commercial milestones.”